- Companies
- Bionano Genomics
Bionano Genomics Valuation Multiples
Bionano Genomics is valued at $17M as of October 2026, a 0.4x revenue multiple. In the last 12 months, Bionano Genomics revenue was $32M.
Bionano Genomics Overview
About Bionano Genomics
Bionano Genomics is a San Diego life-sciences tools company founded in 2007 and listed on Nasdaq under BNGO. It develops optical genome mapping instruments, consumables and software used to detect structural genomic variation. Research laboratories, hospitals and pharmaceutical customers use its Saphyr platform and related informatics in cytogenetics and translational research. Revenue comes from instrument and consumable sales, software and laboratory services. Bionano expanded into genetic testing through the 2020 acquisition of Lineagen. It added BioDiscovery's NxClinical informatics platform in 2021 and Purigen's Ionic Purification System in 2022. These acquisitions broadened the company from a single instrument platform into an end-to-end genome analysis workflow. It remains the public operating company at bionano.com.
Founded
2007
HQ
Employees
100
Website
Financials (LTM)
EV
$14M
Valuation Multiples
Start free trialBionano Genomics Financials
Bionano Genomics reported last 12-month revenue of $32M.
In the same LTM period, Bionano Genomics generated $16M in gross profit and had net loss of ($29M).
Revenue (LTM)
Bionano Genomics P&L
In the most recent fiscal year, Bionano Genomics reported revenue of $29M and EBITDA of ($21M).
Bionano Genomics is unprofitable as of last fiscal year, with gross margin of 46%, EBITDA margin of (74%), and net margin of (93%).
Financial data powered by Morningstar, Inc.
Bionano Genomics Stock Performance
Bionano Genomics has current market cap of $17M, and enterprise value of $14M.
Market Cap Evolution
Bionano Genomics' stock price is $1.47.
Bionano Genomics share price decreased by 6.4% in the last 30 days, and by 17.9% in the last year.
Bionano Genomics has an EPS (earnings per share) of $-2.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $17M | 0.7% | -6.4% | 37.4% | -17.9% | $-2.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBionano Genomics Valuation Multiples
Bionano Genomics trades at 0.4x EV/Revenue multiple, and (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Bionano Genomics Financial Valuation Multiples
As of October 9, 2026, Bionano Genomics has market cap of $17M and EV of $14M.
Bionano Genomics has a P/E ratio of (0.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bionano Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bionano Genomics Margins & Growth Rates
Bionano Genomics grew revenue by 14% and net profit by 11% in the last fiscal year.
In the most recent fiscal year, Bionano Genomics reported gross margin of 46%, EBITDA margin of (74%), and net margin of (93%).
Bionano Genomics Margins
Bionano Genomics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bionano Genomics Operational KPIs
Bionano Genomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Bionano Genomics Competitors
Bionano Genomics competitors include Biosynex, European Medical Solutions, Rhythm Biosciences, OncoSil Medical, Lifeward, Lifecare, SeaStar Medical Holding, Urteste, Elbit Realestate and Labo Euromedis.
Most Bionano Genomics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $107M | ($2M) | 0.7x | 0.7x | (40.5x) | (4.9x) | |||
| $56M | $5M | 0.6x | - | 7.0x | - | |||
| $59K | ($4M) | 261.1x | - | (3.9x) | - | |||
| $1M | ($8M) | 11.6x | 8.4x | (1.8x) | (1.8x) | |||
| $22M | ($19M) | 0.7x | 0.6x | (0.8x) | - | |||
| $12K | ($12M) | 1273.2x | 184.3x | (1.3x) | (1.8x) | |||
| $1M | ($12M) | 9.3x | 6.3x | (0.9x) | - | |||
| $6K | ($1M) | 2913.4x | - | (11.3x) | - | |||
This data is available for Pro users. Sign up to see all Bionano Genomics competitors and their valuation data. Start Free Trial | ||||||||
Bionano Genomics VC Funding History
Before going public, Bionano Genomics raised $120M in total equity funding, across 5 rounds.
Bionano Genomics Funding Rounds
Acquisitions by Bionano Genomics
Bionano Genomics has acquired 3 companies to date.
Last acquisition by Bionano Genomics was on November 28th 2022. Bionano Genomics acquired Purigen Biosystems for undisclosed valuation.
Latest Acquisitions by Bionano Genomics
| Description | Purigen Biosystems was a California life-sciences tools company founded in 2012. It developed the Ionic Purification System, which uses isotachophoresis to isolate DNA and RNA from low-input and difficult biological samples. Academic, clinical and pharmaceutical laboratories used the instrument and consumables before sequencing and genomic analysis. Revenue came from instrument, consumable and service sales. Bionano Genomics announced the acquisition on 28 November 2022 and completed it on 30 November. Bionano paid USD 32 million in cash at closing and agreed to potential additional cash payments tied to development and commercial milestones. The purchase added sample preparation to Bionano's optical genome mapping workflow and retained Purigen personnel. Purigen is now an acquired Bionano operation rather than an independent biotechnology company. | BioDiscovery was a US scientific-software company founded in 1997 and based in the Los Angeles area. It developed NxClinical and related tools for copy-number, structural-variant and sequence analysis across next-generation sequencing and microarray data. Clinical cytogenetics laboratories, research institutions and pharmaceutical users licensed the software for genomic interpretation workflows. Revenue came from software subscriptions, licences and related support. Bionano Genomics announced an agreement to acquire BioDiscovery on 12 October 2021 and completed the purchase on 18 October. The combination brought BioDiscovery's informatics customer base and development team into Bionano's optical genome mapping platform. Founder Soheil Shams joined Bionano as chief informatics officer. BioDiscovery is now an acquired Bionano business and is distinct from similarly named funds and drug-discovery companies. | Lineagen was a Salt Lake City molecular-diagnostics company founded in 2002. It provided genetic testing and counselling for children and families affected by autism and other neurodevelopmental disorders. Clinicians used its laboratory-developed tests and chromosomal microarray services to identify potentially relevant genomic variants. The business generated testing and service revenue through a CLIA-certified laboratory and payer relationships. Bionano Genomics acquired Lineagen through a merger completed on 21 August 2020 and announced the transaction on 24 August. The transaction added a clinical laboratory, genetic counsellors, billing expertise and payer contracts to Bionano's optical genome mapping business. Lineagen is now an acquired Bionano operation rather than an independent diagnostics company. |
| HQ Country | |||
| HQ City | San Francisco, CA | Ann Arbor, MI | Salt Lake City, UT |
| Deal Date | 28 Nov 2022 | 12 Oct 2021 | 24 Aug 2020 |
| Valuation | undisclosed | undisclosed | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Bionano Genomics acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bionano Genomics
| When was Bionano Genomics founded? | Bionano Genomics was founded in 2007. |
| Where is Bionano Genomics headquartered? | Bionano Genomics is headquartered in United States. |
| How many employees does Bionano Genomics have? | As of today, Bionano Genomics has over 100 employees. |
| Who is the CEO of Bionano Genomics? | Bionano Genomics' CEO is R. Erik Holmlin. |
| Is Bionano Genomics publicly listed? | Yes, Bionano Genomics is a public company listed on Nasdaq. |
| What is the stock symbol of Bionano Genomics? | Bionano Genomics trades under BNGO ticker. |
| When did Bionano Genomics go public? | Bionano Genomics went public in 2018. |
| Who are competitors of Bionano Genomics? | Bionano Genomics main competitors include Biosynex, European Medical Solutions, Rhythm Biosciences, OncoSil Medical, Lifeward, Lifecare, SeaStar Medical Holding, Urteste, Elbit Realestate, Labo Euromedis. |
| What is the current market cap of Bionano Genomics? | Bionano Genomics' current market cap is $17M. |
| What is the current revenue of Bionano Genomics? | Bionano Genomics' last 12 months revenue is $32M. |
| What is the current revenue growth of Bionano Genomics? | Bionano Genomics revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Bionano Genomics? | Current revenue multiple of Bionano Genomics is 0.4x. |
| Is Bionano Genomics profitable? | No, Bionano Genomics is not profitable. |
| What is the current net income of Bionano Genomics? | Bionano Genomics' last 12 months net income is ($29M). |
| How many companies Bionano Genomics has acquired to date? | As of October 2026, Bionano Genomics has acquired 3 companies. |
| What was the largest acquisition by Bionano Genomics? | None of the M&A deals Bionano Genomics has completed have disclosed valuations. |
| What companies Bionano Genomics acquired? | Bionano Genomics acquired BioDiscovery, Purigen Biosystems, and Lineagen. |
| In how many companies Bionano Genomics has invested to date? | Bionano Genomics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Bionano Genomics
Lists including Bionano Genomics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




